- REGORAFENIB Broad-Spectrum Kinase Inhibitor Oncolytic
[作者:Marrari, A; George, S,期刊:Drugs of the Future, 页码:17-23 , 文章类型: Article,,卷期:2011年36-1]
- Regorafenib is an orally active inhibitor of VEGFR-2 and -3, c-Kit, TIE-2, PDGF-R-beta, FGFR-7, Ret, c-RAF and MAP kinase p38. Preclinical in vitro and in vivo studies demonstrate a broad spectrum of activity, likely due...
- VASOPEPTIDASE INHIBITION - SOLVING THE CARDIOVASCULAR PUZZLE?
[作者:Douglas, RG; Ehlers, MRW; Sturrock, ED,期刊:Drugs of the Future, 页码:33-43 , 文章类型: Review,,卷期:2011年36-1]
- The therapeutic blockade of the renin-angiotensin-aldosterone system (RAAS) using angiotensin-converting enzyme (ACE) inhibitors, angiotensin,receptor blockers, aldosterone receptor antagonists and, more recently, renin ...
- DENGUE VACCINES: NEW DEVELOPMENTS
[作者:Guzman, MG,期刊:Drugs of the Future, 页码:45-62 , 文章类型: Article,,卷期:2011年36-1]
- Dengue represents a major, growing public health problem, with an estimated of 2.5 billion people at risk of infection and about 50 million cases. Vector control is the only way of controlling dengue transmission; howeve...
|